Adjustments to Warrants of Series TO 2
In alignment with the terms set for warrants of series TO 2, which were first introduced as part of a capital raise, significant recalibrations have been made. This adjustment is a response to the rights issue of units that has been announced by SciBase Holding AB (the "Company" or "SciBase"). The company is committed to ensuring that the terms of the warrants reflect the current structure of its equity and maintain favorable conditions for its holders.
Impact of Rights Issues on Warrants
As part of the recalibration, it has been confirmed that the number of shares each warrant entitles the holder to subscribe for, alongside the subscription price, will remain unchanged despite the new rights offering. Consequently, one (1) warrant of series TO 2 enables the holder to subscribe for one (1) share at a subscription price fixed at SEK 0.42, consistent with prior communications.
Warrant Subscription Period
Each warrant of series TO 2 provides the opportunity to subscribe for one new share within a defined period. This period commences on April 3, 2029, and concludes on April 17, 2029. It's during this window that holders can exercise their rights tied to the warrants.
Transparency in Warrant Terms
The specific terms and conditions governing the warrants, which include any potential changes due to future share issues, are transparently available on the Company’s corporate website. This supports the commitment to maintain clarity and ease of access for investors and stakeholders.
Further Information and Contact
For more detailed inquiries about the recalibrated terms or related matters, individuals may contact:
Pia Renaudin, CEO, tel. +46732069802.
About SciBase
SciBase is a pioneering global medical technology firm focused on the early detection and prevention of skin conditions through innovative dermatological techniques. The company's flagship platform, Nevisense, integrates cutting-edge artificial intelligence and advanced electrical impedance spectroscopy technology to enhance diagnostic precision, paving the way for proactive management of skin health.
Commitment to Patient Care
SciBase is driven by a commitment to reduce patient suffering, equipping clinicians with tools to improve and save lives through accurate, timely detection and intervention. This not only enhances individual patient care but also contributes to lowering healthcare expenditures.
Background and Evolution of SciBase
With over two decades of foundational research conducted at the renowned Karolinska Institute in Stockholm, SciBase stands at the forefront of dermatological innovation. The commitment to improving the early detection of skin issues positions the Company as a leader in the medical technology space.
Conclusion
Since its listing on Nasdaq First North Growth Market, the Company has witnessed substantial growth and has reaffirmed its dedication to transforming the healthcare landscape through groundbreaking technology and unwavering customer service. For ongoing updates and insights, stakeholders are encouraged to visit the Company website.
Frequently Asked Questions
What is the recalculated subscription price for the warrants?
The subscription price has been maintained at SEK 0.42 per share, remaining unchanged after the rights issue.
What rights do the TO 2 warrants provide to holders?
These warrants provide holders the right to subscribe for one new share during the specified period from April 3, 2029, to April 17, 2029.
How does the rights issue affect the existing warrants?
The rights issue has no impact on the number of shares or subscription price related to existing warrants; these terms have stayed consistent.
Where can I find more information about SciBase’s technology?
Additional details regarding SciBase's innovative technology and products can be found on their official website.
Who can I contact for more information regarding the warrants?
For inquiries, please contact Pia Renaudin, CEO, at the provided contact number.
